Table 1.
Baseline characteristics of study population.
| Category | Variable | Entire data set (n = 983) |
|---|---|---|
| Target variable | The next TDM, ng/ml, n (%) | 32.9 (23.3–46.5) |
| Condition of risperidone use | The initial TDM, ng/ml, median (IQR) | 24.9 (17.1–36.3) |
| Risperidone dose, mg, median (IQR) | 4.0 (3.0–5.0) | |
| TDM interval, days, median (IQR) | 7 (6–9) | |
| Demographic information | Age, year, median (IQR) | 37.0 (29.0–50.0) |
| Sex, n (%) | ||
| Male | 454.0 (46.2%) | |
| Female | 529.0 (53.8%) | |
| Height, cm, median (IQR) | 165.0 (160.0–172.0) | |
| Weight, kg, median (IQR) | 66.0 (57.0–76.0) | |
| BMI, kg/m2, median (IQR) | 24.0 (20.9–27.3) | |
| Combination | 5-HT, n (%) | 47.0 (4.8%) |
| CYP2D6 enzyme inducers | 1.0 (0.1%) | |
| Other_CYP2D6 enzyme inhibitors | 250.0 (25.4%) | |
| Citalopram | 13.0 (1.3%) | |
| Haloperidol | 13.0 (1.3%) | |
| Sertraline | 13.0 (1.3%) | |
| Assay index | PLT, 109/L, median (IQR) | 244.0 (207.0–290.0) |
| WBC, 1012/L, median (IQR) | 6.5 (5.3–7.9) | |
| RBC, 109/L, median (IQR) | 4.6 (4.2–4.9) | |
| BUN, mmol/L, median (IQR) | 3.7 (3.0–4.5) | |
| Cr, μmol/L, median (IQR) | 60.0 (52.0–70.0) | |
| Ccr, ml/min, median (IQR) | 123.8 (101.9–148.7) | |
| AST, U/L, median (IQR) | 16.4 (13.4–22.1) | |
| ALT, U/L, median (IQR) | 17.8 (11.9–27.1) | |
| PRL, μg/L, median (IQR) | 62.8 (38.0–107.7) | |
| Last PRL, μg/L, median (IQR) | 40.7 (28.3–73.4) | |
| PRL_change rate, %, median (IQR) | 0.3 (0.1–1.0) | |
| Other therapy | Using MECT within 1 week before TDM | 288.0 (29.3%) |
IQR, inter quartile range; TDM, therapeutic drug monitoring; BMI, body mass index; PLT, platelet; RBC, red blood cells; WBC, white blood cells; BUN, blood urea nitrogen; Cr, serum creatinine; Ccr, creatinine clearance rate; ALT, alanine transaminase; AST, aspartate transaminase; PRL, prolactin; MECT, modified electroconvulsive therapy.